OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases $192,166.47 in Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Patrick W. Smith purchased 90,219 shares of OncoCyte stock in a transaction dated Thursday, December 26th. The shares were acquired at an average cost of $2.13 per share, for a total transaction of $192,166.47. Following the transaction, the insider now directly owns 1,773,903 shares of the company’s stock, valued at approximately $3,778,413.39. This represents a 5.36 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

OncoCyte Stock Down 2.9 %

Shares of NASDAQ:OCX opened at $2.38 on Thursday. OncoCyte Co. has a fifty-two week low of $1.97 and a fifty-two week high of $3.82. The firm’s 50 day moving average price is $2.58 and its 200 day moving average price is $2.89.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same period in the prior year, the business posted ($0.57) earnings per share. Analysts expect that OncoCyte Co. will post -2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC increased its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the quarter. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 55.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. StockNews.com initiated coverage on shares of OncoCyte in a report on Wednesday. They set a “sell” rating on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.